Saphris (Asenapine Maleate) Patent Expiration, LOE Window & CMS Spending

Saphris (Asenapine Maleate) by AbbVie: FDA Orange Book core substance LOE 2026-10-06, 3 AB generics, $26.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN022117 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-10-06
Last Listed Patent or Exclusivity Date2026-10-06
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$26.7M
2024 Medicare Part D Spend$7.2M
2024 Medicaid Spend$19.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.